Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Oreofe O. Odejide et al.|Blood Advances|2020Cited by 58
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)Austin Kim, Mark A. Murakami, Peter A. Riedell et al.|Blood|2025Cited by 4
Handbook of Stem Cell Transplantation and Cellular Therapy ManagementEdwin P. Alyea, Ibrahim N. Muhsen, Vincent T. Ho et al.|Unknown|2020Cited by 1
Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximabHari S. Raman, Reid W. Merryman, Robert Redd et al.|Blood|2025Cited by 0
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trialReid W. Merryman, Joshua Brody, Gottfried von Keudell et al.|Blood|2025Cited by 0